The company's lead candidate, ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. In November 2024, the company announced it had entered ENV-294 into a Phase I clinical trial, with the first patient dosed at the end of October.